-
Mashup Score: 0
The company also submitted data from the ongoing phase 2 study, demonstrating the improvements of the investigational drug for symptoms of overall disease severity.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 0VLA1553 Chikungunya Virus Vaccine Shows Antibody Persistence Up to 2 Years Following Administration - 19 hour(s) ago
The investigators of the phase 3b trial (NCT04838444) will continue to follow up with patients for up to 10 years.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
Vaccination with VLA1553 is a safe, efficient intervention that offers high seroprotection against #infection from the #chikungunya virus, with no long-term serious adverse events reported. Learn more: https://t.co/ko315Twck1
-
-
Mashup Score: 5Patients With Difficult-To-Treat Asthma Require Different Intervention Methods Based on Comorbidities - 23 hour(s) ago
To help with treatment response and compliance as well as optimize treatment, communication between patients and health care providers is necessary.
Source: www.pharmacytimes.comCategories: General Medicine News, PayerTweet-
Managing difficult-to-treat #asthma requires a personalized approach considering factors like #obesity, #allergies, and acid #reflux, along with ensuring an open line of communication between patients and health care providers. #Pharmacy Read more: https://t.co/STKvJybNvz
-
-
Mashup Score: 1IVIG Associated With Shorter Hospital, ICU Length of Stay in Immunocompromised Patients With Respiratory Infections - 1 day(s) ago
When IVIG was administered within 48 hours of hospital admission, hospital and ICU length of stay were dramatically shortened.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
In patients with #respiratory infections, #intravenous #immunoglobulin was associated with shorter hospital and intensive care unit length of stay. #IVIG #Pharmacy #ICU Learn more: https://t.co/myPQZwRWEu
-
-
Mashup Score: 1
Lalan Wilfong, MD, discusses the road to value-based care and payment reform in cancer care.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
At #COA 2024, Lalan Wilfong, MD, discusses the positive role that value-based care has in #oncology, as it emphasizes collaboration between #patient and provider and can optimize new #drugs for specific patient care. Watch: https://t.co/Ron0tzlcPR
-
-
Mashup Score: 0Expert: MARIPOSA Study Shows No Significant Differences Between Lazertinib and Osimertinib for NSCLC - 2 day(s) ago
Lazertinib with amivantamab was found to be similar in efficacy to osimertinib in the MARIPOSA study.
Source: www.pharmacytimes.comCategories: General Medicine News, PayerTweet-
Alex Spira, MD, PhD, FACP, FASCO, discussed the results from the MARIPOSA trial that showed little difference between the combination of lazertinib & amivantamab with osimertinib in patients with non-small cell #lung cancer. #NSCLC #WCLC #Oncology Watch: https://t.co/Qe183HLk2u
-
-
Mashup Score: 1
Presenter Krish Patel, MD, discusses the use of epcoritamab (Epkinly; AbbVie) and glofitamab (Columvi; Genentech) in aggressive B-cell lymphomas as monotherapies and in combination regimens.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
#Bispecific antibodies, like epcoritamab and glofitamab, show promise in treating relapsed or refractory aggressive B-cell #lymphomas, warranting further research for optimal use. #SOHO #Oncology #Hematology Learn more: https://t.co/jePdI8xZIc
-
-
Mashup Score: 0
Despite the new human case, which is not known to be related to animal exposure, the CDC emphasizes that risk to the general public remains low.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
The #CDC has confirmed a new human case of #H5N1 #bird flu in Missouri, which is the first case without any known occupational exposure to infected animals, though risk to the general public remains low. #Influenza #Pharmacy Learn more: https://t.co/yIyG0yBQ5o
-
-
Mashup Score: 0
New transparency initiatives will go into effect on January 1, 2025, building off previous actions by the Centers of Medicare and Medicaid Services.
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
Starting January 1, 2025, #hospitals must make public standard charges and additional data in machine-readable files, according to new Centers for Medicare & Medicaid hospital #transparency requirements going into effect. #CMS Learn more: https://t.co/6TU7EKM9bT
-
-
Mashup Score: 10
Edaravone and dexborneol sublingual tablets are an innovative first drug to be designed for treatment of stroke and granted this designation.
Source: www.pharmacytimes.comCategories: General Medicine News, PayerTweet-
Sanbexin, a sublingual tablet for acute ischemic #stroke, received #FDA breakthrough therapy designation for its promising clinical trial results. #Pharmacy Learn more: https://t.co/m9hTmqVTcI
-
#FDA News: AISA-021 (cilnidipine; Aisa Pharma, Inc), a fourth-generation #calcium channel antagonist, was granted orphan drug designation by the FDA for the treatment of patients with systemic #sclerosis. #Pharmacy Learn more: https://t.co/J2jMJiAfs1